S. Morita

发表

Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study

T. Mimori, Hiromu Ito, Tamami Yoshida, 2018, Rheumatology International.

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

J. Sakamoto, M. Hino, S. Kimura, 2017, Internal medicine.

F1000 highlights

A. Gemma, Tomoaki Tanaka, S. Morita, 2010 .

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

S. Toyooka, Y. Yatabe, T. Mitsudomi, 2010, The Lancet. Oncology.

CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.

T. Kanauchi, S. Morita, T. Baba, 2014, European journal of radiology.

An adaptive power prior for sequential clinical trials – Application to bridging studies

Satoshi Morita, Moreno Ursino, Sarah Zohar, 2019, Statistical methods in medical research.

Positive Outcomes of High Hemoglobin Target in Patients With Chronic Kidney Disease Not on Dialysis: A Randomized Controlled Study

S. Fukuhara, M. Iwasaki, S. Morita, 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Preoperative chemotherapy is effective for stage III resectable non--small-cell lung cancer: metaanalysis of 16 trials.

N. Horita, S. Morita, Y. Ishigatsubo, 2013, Clinical lung cancer.

PREOPERATIVE INNER SEGMENT/OUTER SEGMENT JUNCTION IN SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS A PROGNOSTIC FACTOR IN EPIRETINAL MEMBRANE SURGERY

S. Morita, K. Kadonosono, M. Inoue, 2011, Retina.

Femoral head collapse rate among Japanese patients with pre-collapse osteonecrosis of the femoral head

Sakae Tanaka, N. Sugano, S. Matsuda, 2021, The Journal of international medical research.

Bayesian dose‐finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology

S. Morita, Kentaro Takeda, Kanji Komatsu, 2018, Pharmaceutical statistics.

Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial

S. Morita, Fumihiro Takahashi, 2018, Journal of biopharmaceutical statistics.

Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial

S. Morita, Kentaro Takeda, 2018, Pharmaceutical statistics.

Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem

S. Morita, Kentaro Takeda, 2015, Therapeutic innovation & regulatory science.

Biomarker‐based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation

S. Morita, Hideharu Yamamoto, Yasuo Sugitani, 2014, Statistics in medicine.

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2006, Japanese journal of clinical oncology.

Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations

S. Morita, M. Taguri, M. Morimoto, 2012, International Journal of Clinical Oncology.

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

K. Muro, K. Chìn, S. Morita, 2018, Gastric Cancer.

4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study

S. Morita, Koji Matsumoto, H. Sakai, 2021, International Journal of Clinical Oncology.

Analysis of incomplete quality of life data in advanced stage cancer: A practical application of multiple imputation

M. Shibuya, K. Eguchi, Y. Ohashi, 2005, Quality of Life Research.

A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).

Y. Maehara, J. Sakamoto, S. Morita, 2007, Japanese Journal of Clinical Oncology.

Characteristics of suicide attempters with family history of suicide attempt: a retrospective chart review

Y. Hirayasu, S. Morita, C. Kawanishi, 2009, BMC psychiatry.

Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial

S. Morita, Akira Shimizu, H. Abe, 2021, Plastic and reconstructive surgery. Global open.

Iron and iodine deficiencies among under-2 children, adolescent girls, and pregnant women of Bangladesh: association with common diseases.

J. Sakamoto, S. Morita, M. Harun-Or-Rashid, 2009, Nagoya journal of medical science.

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

A. Gemma, Tomoaki Tanaka, S. Morita, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial

N. Masuda, Masato Takahashi, R. Uozumi, 2021, Breast Cancer Research and Treatment.

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer

J. Sakamoto, S. Morita, S. Takao, 2012, Cancer Chemotherapy and Pharmacology.

Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.

T. Ishikawa, H. Shimada, S. Morita, 2009, Anticancer research.

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer

S. Morita, I. Ikeda, M. Taguri, 2015, BMC Cancer.

J. Sakamoto, N. Hamajima, S. Morita, 2007, Nagoya journal of medical science.

Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.

S. Natsugoe, J. Sakamoto, T. Aikou, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Implications of Peritoneal Cytology in Potentially Resectable Pancreatic Cancer: Positive Peritoneal Cytology May Not Confer an Adverse Prognosis

S. Yamada, T. Fujii, H. Sugimoto, 2007, Annals of surgery.

A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Y. Ohashi, S. Morita, A. Takeuchi, 2008, Japanese journal of clinical oncology.

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

Y. Ohashi, N. Masuda, S. Morita, 2009, Supportive Care in Cancer.

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

Y. Hosomi, M. Ando, M. Kondo, 2022, Journal of Thoracic Oncology.

Different learning curves between stent retrieval and a direct aspiration first-pass technique for acute ischemic stroke.

S. Morita, I. Nakahara, I. Nagata, 2018, Journal of neurosurgery.

Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring

Kazuhiro Yoshida, M. Buyse, J. Sakamoto, 2019, Clinical trials.

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

H. Eguchi, H. Nagano, M. Unno, 2018, Cancer Immunology Research.

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris.

S. Takanashi, S. Morita, M. Tabata, 2013, The Journal of thoracic and cardiovascular surgery.

Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1

T. Ogihara, K. Shimada, S. Ito, 2014, Journal of hypertension.

Angiotensin receptor blocker (ARB)–diuretic versus ARB–calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy

Y. Toya, S. Umemura, G. Yasuda, 2014, Clinical and experimental hypertension.

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies

I. Kawase, S. Morita, Toshinori Ito, 2019, Medicine.

Anemia affects the quality of life of Japanese cancer patients.

K. Eguchi, Y. Ohashi, S. Morita, 2013, The Tokai journal of experimental and clinical medicine.

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.

T. Ogihara, M. Fujishima, Mahbubur Rahman, 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

E. Tokunaga, M. Yamaguchi, N. Masuda, 2017, Breast Cancer Research and Treatment.

A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.

I. Endo, T. Ishikawa, H. Shimada, 2010, Japanese journal of clinical oncology.

Local control of sphincter‐preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis

F. Fujita, M. Okajima, Takao Takahashi, 2017, Annals of gastroenterological surgery.

Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.

I. Endo, Kimito Yamada, T. Ishikawa, 2020, Surgical oncology.

A prophylaxis study of acute exacerbation of interstitial pneumonia after lung cancer surgery.

S. Morita, M. Masuda, T. Yokose, 2020, Japanese journal of clinical oncology.

Surgical outcomes of laparoscopy-assisted gastrectomy versus open gastrectomy for gastric cancer: a case-control study

I. Endo, S. Morita, M. Taguri, 2012, Surgical Endoscopy.

Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.

S. Umemura, S. Morita, K. Hibi, 2012, Circulation journal : official journal of the Japanese Circulation Society.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka, H. Shimodaira, S. Morita, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of a negative history of smoking on survival in patients with non-small cell lung cancer detected with clinic-based screening programs.

S. Morita, Y. Ishigatsubo, T. Kaneko, 2012, Internal medicine.

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients

M. Sugimoto, R. Uozumi, S. Morita, 2018, Breast Cancer.

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

T. Ishikawa, N. Kondo, K. Tsugawa, 2020, Breast Cancer.

Randomized controlled trial of the significance of combined use with Ninjin’yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer

E. Baba, S. Morita, T. Nishiuchi, 2022, Medicine: Case Reports and Study Protocols.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

M. Buyse, Tae Won Kim, J. Sakamoto, 2016, Chinese journal of cancer.

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Kazuhiro Yoshida, Masato Nakamura, H. Matsumoto, 2013, The Lancet. Oncology.

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

I. Hyodo, H. Kuwano, K. Muro, 2010, The Lancet. Oncology.

A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer

T. Yano, R. Ishihara, H. Isomoto, 2016, Oncotarget.

Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial)

Y. Kodera, K. Misawa, S. Morita, 2019, The British journal of surgery.

A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial

M. Kanda, Y. Kodera, T. Yoshikawa, 2018, Gastric Cancer.

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102).

Y. Kodera, Kazuhiro Yoshida, J. Sakamoto, 2013 .

Recruitment of patients for a clinical trial: factors on the physician side and reasons on the patient side.

Mahbubur Rahman, T. Fukui, J. Sakamoto, 2006, Internal medicine.

Physicians’ Attitudes towards and Reasons for Participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial

Mahbubur Rahman, T. Fukui, J. Sakamoto, 2005, Journal of epidemiology.

Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease

N. Horita, S. Morita, Y. Ishigatsubo, 2014, Respiratory Research.

Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.

S. Umemura, S. Morita, K. Hibi, 2011, Journal of cardiology.

Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma

A. Yoshizawa, M. Sonobe, H. Date, 2022, Journal of Thoracic Oncology.

Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size

S. Morita, K. Sakamaki, N. Boku, 2017, ESMO Open.

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

U. Tateishi, S. Noguchi, S. Morita, 2014, BMC Cancer.

Magnifying endoscope with NBI to predict the depth of invasion in laryngo‐pharyngeal cancer

J. Ito, S. Morita, I. Tateya, 2015, The Laryngoscope.

The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.

Masato Nakamura, K. Muro, S. Morita, 2015, Future oncology.

S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial

N. Tomita, T. Kusumoto, S. Morita, 2021, ESMO open.

S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.

N. Tomita, Kazuhiro Yoshida, T. Kusumoto, 2019, Clinical colorectal cancer.

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

M. Ando, E. Baba, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO)

J. Sakamoto, S. Morita, M. Gosho, 2015, Cancer Chemotherapy and Pharmacology.

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

J. Sakamoto, S. Morita, M. Shimada, 2013, Cancer Chemotherapy and Pharmacology.

Title Study protocol of the TRICOLORE trial : A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1 , irinotecan , and bevacizumab as first-line therapy for metastatic colorectal cancer

C. Ishioka, S. Morita, Tatsuro Yamaguchi, 2018 .

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

Kazuhiro Yoshida, Masato Nakamura, H. Matsumoto, 2017, ESMO Open.

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

C. Ishioka, S. Morita, Tatsuro Yamaguchi, 2015, BMC Cancer.

A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study

M. Unno, K. Hasegawa, K. Muro, 2022, Langenbeck's archives of surgery (Print).

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer

Masato Nakamura, Tae Won Kim, J. Sakamoto, 2021, Cancer science.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Masato Nakamura, Tae Won Kim, J. Sakamoto, 2018, The Lancet. Oncology.

Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs

K. Yonemori, S. Morita, T. Urano, 2014, Therapeutic innovation & regulatory science.

Planned Safety Analysis of the ACTS‐CC 02 Trial: A Randomized Phase III Trial of S‐1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High‐Risk Stage III Colon Cancer

N. Tomita, Kazuhiro Yoshida, T. Kusumoto, 2017, Clinical colorectal cancer.

Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases

S. Okamura, K. Muro, S. Morita, 2020, Medicine.

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

J. Sakamoto, S. Morita, T. Nagasaka, 2019, Medical Oncology.

The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2018, Journal of Cancer.

Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).

J. Sakamoto, S. Morita, M. Shimada, 2009, Japanese journal of clinical oncology.

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).

M. Satouchi, T. Nishimura, S. Morita, 2015, Lung cancer.

Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

K. Muro, S. Morita, H. Baba, 2020, Global health & medicine.

Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701)

Y. Kodera, S. Morita, H. Kojima, 2016, International Journal of Clinical Oncology.

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

Yukiko Nakamura, T. Yamanaka, S. Morita, 2020, JTO clinical and research reports.

Treatment Rationale and Design for J‐AXEL: A Randomized Phase 3 Study Comparing Nab‐Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small‐Cell Lung Cancer

Y. Hosomi, M. Ando, M. Kondo, 2017, Clinical lung cancer.

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).

S. Morita, K. Azuma, Y. Koh, 2019, Lung cancer.

Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2016, European journal of cancer.

A Methylene Blue–assisted Technique for Harvesting Lymph Nodes After Radical Surgery for Gastric Cancer

T. Yoshikawa, S. Morita, Tsutomu Hayashi, 2015, The American journal of surgical pathology.

Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: results of a prospective multi-institutional comparative trial

Y. Kodera, M. Ando, M. Fujiwara, 2015, Gastric Cancer.

A randomized phase III trial exploring the prognostic value of extensive intraoperative peritoneal lavage in addition to standard treatment for resectable advanced gastric cancer: CCOG 1102 study.

Y. Kodera, K. Misawa, S. Morita, 2014, Japanese journal of clinical oncology.

Accuracy of CT Staging of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: Cohort Evaluation within a Randomized Phase II Study

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2014, Annals of Surgical Oncology.

Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study

S. Morita, M. Taguri, C. Kunisaki, 2013, Gastric Cancer.

Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for operable gastric cancer, a randomized Phase II trial (LANDSCOPE trial).

T. Yoshikawa, S. Morita, M. Taguri, 2012, Japanese journal of clinical oncology.

Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale

K. Eguchi, Y. Ohashi, S. Morita, 2006, Supportive Care in Cancer.

Depression in Japanese Patients With Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study

N. Horita, B. Rubin, S. Morita, 2013, Respiratory Care.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Differences in negative T waves between takotsubo cardiomyopathy and reperfused anterior acute myocardial infarction.

S. Umemura, S. Morita, K. Hibi, 2012, Circulation journal : official journal of the Japanese Circulation Society.

Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction.

S. Umemura, S. Morita, K. Hibi, 2010, Journal of the American College of Cardiology.

Lifestyle and work predictors of fatigue in Japanese manufacturing workers.

Satoshi Morita, Taichiro Tanaka, Tomonori Okamura, 2007, Occupational medicine.

Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians

Mahbubur Rahman, T. Fukui, J. Sakamoto, 2006, Hypertension Research.

A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.

H. Nagano, E. Hatano, S. Morita, 2019, Annals of surgery.

Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study

H. Eguchi, H. Nagano, E. Hatano, 2014, Cancer Chemotherapy and Pharmacology.

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

T. Nakao, J. Sakamoto, J. Nishida, 2018, International Journal of Clinical Oncology.

Serum milk fat globule epidermal growth factor 8 elevation may subdivide systemic lupus erythematosus into two pathophysiologically distinct subsets

K. Ohmura, T. Mimori, S. Nagata, 2014, Lupus.

Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.

S. Umemura, S. Morita, K. Hibi, 2010, Circulation journal : official journal of the Japanese Circulation Society.

"Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.

S. Morita, T. Eto, S. Fujimoto, 2005, Journal of nephrology.

Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes.

Y. Terauchi, S. Morita, H. Shigematsu, 2012, Journal of atherosclerosis and thrombosis.

Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD)

S. Fukuhara, S. Morita, T. Akizawa, 2005, Clinical and Experimental Nephrology.

Truth-telling to Patients with Advanced Cancer: A Comparison between Cancer center, University Hospitals, General City Hospitals, and Private General Practitioners in Japan

J. Sakamoto, S. Morita, A. Nakao, 2006 .

Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial

Y. Miyagi, T. Yoshikawa, J. Sakamoto, 2020, Oncotarget.

Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial.

T. Yoshikawa, Masato Nakamura, J. Sakamoto, 2020, European journal of cancer.

A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).

Y. Miyagi, T. Yoshikawa, J. Sakamoto, 2018, European journal of cancer.

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis

S. Morita, K. Sakamaki, A. Takashima, 2018, Cancer Chemotherapy and Pharmacology.

Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper

T. Yamanaka, J. Sakamoto, S. Morita, 2017 .

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.

T. Yoshikawa, Masato Nakamura, J. Sakamoto, 2015, European journal of cancer.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

S. Park, Tae-You Kim, K. Nishio, 2014, Gastric Cancer.

Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

J. Sakamoto, Y. Miyoshi, T. Taguchi, 2014, Anticancer research.

Prognostic factors in stage IB gastric cancer.

T. Yoshikawa, Takanobu Yamada, S. Morita, 2014, World journal of gastroenterology.

RETROSPECTIVE STUDY Prognostic factors in stage IB gastric cancer

T. Yoshikawa, Takanobu Yamada, S. Morita, 2014 .

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis

J. Sakamoto, K. Tanabe, S. Morita, 2014, Cancer Chemotherapy and Pharmacology.

Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case

T. Yoshikawa, J. Sakamoto, S. Morita, 2012, Surgery Today.

A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial).

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2011, Japanese journal of clinical oncology.

Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)

J. Sakamoto, S. Saji, S. Morita, 2011, Oncology.

A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

T. Yoshikawa, Masato Nakamura, J. Sakamoto, 2019, Cancer Chemotherapy and Pharmacology.

Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2016, Gastric Cancer.

A randomized phase II trial of omentum-preserving gastrectomy for advanced gastric cancer.

T. Yoshikawa, S. Morita, M. Taguri, 2013, Japanese journal of clinical oncology.

A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2010, Japanese journal of clinical oncology.

Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity

N. Matsumoto, S. Morita, M. Taguri, 2012, Journal of Human Genetics.

Delayed antigen-specific CD4+ T-cell induction correlates with impaired immune responses to SARS-COV-2 mRNA vaccination in the elderly

S. Morita, Masaki Yamamoto, M. Nagao, 2022, bioRxiv.

Evaluation of the chronic obstructive pulmonary disease assessment test in Japanese outpatients

N. Horita, S. Morita, M. Shinkai, 2014, The clinical respiratory journal.

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study

J. Kigawa, M. Shimada, S. Morita, 2017, Medical Oncology.

gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials

S. Morita, M. Taguri, Kentaro Takeda, 2022, Biometrical journal. Biometrische Zeitschrift.

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

A. Gemma, S. Morita, Kunihiko Kobayashi, 2020, BMC Cancer.

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

N. Masuda, Masato Takahashi, M. Yamashita, 2022, BMC Medicine.

Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.

M. Sonobe, H. Date, M. Hiraoka, 2015, The Annals of thoracic surgery.

An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.

S. Umemura, S. Morita, K. Hibi, 2011, The American journal of cardiology.

Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.

N. Yorioka, S. Fukuhara, S. Morita, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients

S. Fukuhara, K. Aonuma, S. Morita, 2010, Clinical and Experimental Nephrology.

Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study

C. Terao, K. Ohmura, T. Mimori, 2018, Scandinavian journal of rheumatology.

Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection

S. Morita, H. Horio, M. Harada, 2015, Annals of Surgical Oncology.

Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.

J. Sakamoto, S. Kyo, M. Inoue, 2009, Anticancer research.

The domain structure of the EORTC QLQ‐STO22 supported by Japanese validation data

J. Sakamoto, S. Morita, K. Oba, 2008, Psycho-oncology.

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.

A. Gemma, S. Morita, Kunihiko Kobayashi, 2012, The oncologist.

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

T. Yoshimine, J. Sakamoto, S. Morita, 2015, Cancer Immunology, Immunotherapy.

Gender differences in patients undergoing surgery for acute type A aortic dissection.

S. Takanashi, S. Morita, M. Tabata, 2015, The Journal of thoracic and cardiovascular surgery.

Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective randomized phase III study

T. Yoshikawa, S. Morita, T. Oshima, 2014, BMC Cancer.

Risk analysis and improvement of strategies in patients who have acute type A aortic dissection with coronary artery dissection.

S. Morita, M. Masuda, K. Uchida, 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.

S. Umemura, S. Morita, K. Hibi, 2009, Circulation journal : official journal of the Japanese Circulation Society.

No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation

K. Umeshita, E. Hatano, H. Ohdan, 2022, Journal of hepato-biliary-pancreatic sciences.

Long-Term Outcomes of Hepatic Resection versus Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Propensity Score-Matching Study

E. Hatano, S. Morita, S. Uemoto, 2015, Disease markers.

Clinical Characteristics of Influenza-Associated Pneumonia of Adults: Clinical Features and Factors Contributing to Severity and Mortality

K. Kurashima, Yotaro Takaku, N. Takayanagi, 2017, The Yale journal of biology and medicine.

Clinical and Radiographic Comparison of Influenza Virus-associated Pneumonia among Three Viral Subtypes.

Yotaro Takaku, T. Hoshi, T. Kanauchi, 2016, Internal medicine.

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

A. Gemma, S. Morita, Kunihiko Kobayashi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

S. Toyooka, Y. Yatabe, T. Mitsudomi, 2012 .

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).

M. Satouchi, S. Morita, S. Fujita, 2013, Japanese journal of clinical oncology.

A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)

M. Satouchi, S. Morita, J. Uchida, 2013, Cancer Chemotherapy and Pharmacology.

Japanese Lung Cancer Society Guideline for stage IV non-small cell lung cancer with epidermal growth factor receptor mutations

Yukiko Nakamura, T. Yamanaka, S. Morita, 2021 .

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.

M. Seike, M. Okada, S. Morita, 2021, The Lancet. Respiratory medicine.

The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives

S. Morita, T. Seto, T. Hida, 2021, Haigan.

A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).

M. Seike, K. Sugio, S. Morita, 2020, Clinical lung cancer.

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial

N. Masuda, S. Morita, M. Toi, 2020, Cancer medicine.

A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation.

S. Morita, H. Kojima, K. Ohashi, 2016, Molecular and clinical oncology.

Breathing–swallowing discoordination is associated with frequent exacerbations of COPD

Y. Oku, S. Muro, R. Uozumi, 2017, BMJ Open Respiratory Research.

Web-based Recruiting for a Survey on Knowledge and Awareness of Cervical Cancer Prevention Among Young Women Living in Kanagawa Prefecture, Japan

S. Garland, J. Wark, E. Miyagi, 2014, International Journal of Gynecologic Cancer.

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

M. Kudo, J. Furuse, S. Morita, 2019, Investigational New Drugs.

Diagnostic Value of Computed Tomography for Staging of Clinical T1 Gastric Cancer

S. Morita, M. Masuda, T. Ogata, 2014, Annals of Surgical Oncology.

Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms.

S. Morita, M. Taguri, M. Morimoto, 2013, Gastrointestinal endoscopy.

Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

H. Nishiyama, M. Tsutsumi, O. Ogawa, 2021, Journal of geriatric oncology.

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)

T. Yoshikawa, K. Okuno, J. Sakamoto, 2017, Cancer Chemotherapy and Pharmacology.

Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis

C. Terao, T. Mimori, Hiromu Ito, 2018, Modern rheumatology.

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study

E. Tokunaga, M. Yamaguchi, N. Masuda, 2021 .

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study

E. Tokunaga, M. Yamaguchi, N. Masuda, 2019, Breast Cancer.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study

E. Tokunaga, M. Yamaguchi, N. Masuda, 2018, Current medical research and opinion.

Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors.

M. Hiraoka, S. Morita, M. Kokubo, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Implications of ST-segment elevation in leads V5 and V6 in patients with reperfused inferior wall acute myocardial infarction.

S. Umemura, S. Morita, K. Hibi, 2012, The American journal of cardiology.

The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.

N. Horita, S. Morita, N. Yamamoto, 2019, Lung cancer.

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

Y. Kogure, M. Satouchi, K. Nishio, 2014, Oncotarget.

The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients

S. Morita, M. Toi, T. Ueno, 2017, npj Precision Oncology.

A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies

S. Morita, T. Kakizume, 2014, Therapeutic innovation & regulatory science.

Hydroxyurea Suppresses HCV Replication in Humans: A Phase I Trial of Oral Hydroxyurea in Chronic Hepatitis C Patients

N. Kato, M. Ikeda, S. Morita, 2010, Antiviral therapy.

Bayesian decision theory for clinical trials: Utility and sample size determination

S. Morita, Fumihiro Takahashi, K. Sakamaki, 2020, Japanese Journal of Biometrics.

Extensive reconstruction of the left anterior descending coronary artery with an internal thoracic artery graft.

S. Takanashi, S. Morita, M. Taguri, 2011, The Annals of thoracic surgery.

Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreas.

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.

S. Umemura, S. Morita, K. Hibi, 2013, Journal of cardiology.

admitted withi n6ho fsymptom onset. Further studies in larger numbers of patients are needed to verify our results.

S. Umemura, S. Morita, K. Hibi, 2010 .

Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan

S. Fukuhara, M. Iwasaki, S. Morita, 2011, Clinical and Experimental Nephrology.

Combined prognostic utility of white blood cell count, plasma glucose, and glomerular filtration rate in patients undergoing primary stent placement for acute myocardial infarction.

C. Tei, M. Yamagishi, S. Morita, 2009, The American journal of cardiology.

Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study

S. Morita, Takashi Sato, Y. Ishigatsubo, 2011, BMJ Open.

Differences in negative T waves among acute coronary syndrome, acute pulmonary embolism, and Takotsubo cardiomyopathy

S. Umemura, S. Morita, K. Hibi, 2012, European heart journal. Acute cardiovascular care.

Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.

S. Umemura, S. Morita, K. Hibi, 2012, Circulation journal : official journal of the Japanese Circulation Society.

Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11.

I. Endo, Y. Hayashizaki, T. Ishikawa, 2010, Anticancer research.

β-Blocker Prescription and Outcomes in Hemodialysis Patients from The Japan Dialysis Outcomes and Practice Patterns Study

S. Fukuhara, S. Morita, T. Akiba, 2009, Nephron Clinical Practice.

Efficacy of continuous versus intermittent subglottic secretion drainage in preventing ventilator-associated pneumonia in patients requiring mechanical ventilation: A single-center randomized controlled trial

S. Morita, K. Kurahashi, T. Goto, 2018, Oncotarget.

Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies

K. Ohmura, T. Mimori, Hiromu Ito, 2017, Rheumatology.

Sleep disordered breathing and metabolic comorbidities across sex and menopausal status in East Asians: the Nagahama Study

T. Kawaguchi, F. Matsuda, T. Hirai, 2020, European Respiratory Journal.

Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer

S. Yamada, T. Fujii, H. Sugimoto, 2012, Annals of surgery.

Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials.

Y. Kodera, M. Fujiwara, S. Morita, 2010, Journal of the American College of Surgeons.

Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreas.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study

E. Tokunaga, Tsuyoshi Saito, N. Masuda, 2018, Breast cancer : basic and clinical research.

Title High testosterone levels in prostate tissue obtained by needle biopsycorrelate with poor-prognosis factors in prostate cancer patients

S. Morita, N. Nonomura, N. Masumori, 2019 .

Sequential free right internal thoracic artery grafting for multivessel coronary artery bypass grafting.

S. Takanashi, S. Morita, M. Tabata, 2012, Journal of Thoracic and Cardiovascular Surgery.

Arterial graft deterioration one year after coronary artery bypass grafting.

S. Takanashi, S. Morita, T. Shimokawa, 2010, The Journal of thoracic and cardiovascular surgery.

Angiographic outcomes of right internal thoracic artery grafts in situ or as free grafts in coronary artery bypass grafting.

S. Takanashi, S. Morita, T. Shimokawa, 2010, The Journal of thoracic and cardiovascular surgery.

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

J. Sakamoto, M. Hino, S. Kimura, 2015, The Lancet. Haematology.

Predictive factors for structural remission using abatacept: Results from the ABROAD study

K. Ohmura, T. Mimori, S. Morita, 2018, Modern rheumatology.

Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands

S. Morita, Hirotoshi Ito, Y. Kawahito, 2017, International journal of rheumatic diseases.

Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study

K. Ohmura, T. Mimori, S. Morita, 2016, The Journal of Rheumatology.

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

S. Morita, M. Tanioka, S. Negoro, 2013, British Journal of Cancer.

Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.

Y. Terauchi, S. Morita, M. Taguri, 2016, Endocrine journal.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01

H. Doihara, Y. Wada, H. Iwata, 2020, Breast Cancer.

Phase I Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

J. Sakamoto, D. Ichikawa, S. Morita, 2004, Oncology.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Quality of life in gastric cancer.

J. Sakamoto, S. Morita, A. Kaptein, 2005, World journal of gastroenterology.

Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

T. Yamanaka, J. Sakamoto, S. Morita, 2019, Gastric Cancer.

Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey†

A. Gemma, S. Morita, N. Boku, 2013, Japanese journal of clinical oncology.

Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.

J. Sakamoto, T. Taguchi, N. Masuda, 2014, Japanese journal of clinical oncology.

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

H. Iwata, N. Masuda, S. Morita, 2017, Breast Cancer.

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey

N. Masuda, S. Morita, M. Toi, 2009, Breast Cancer Research and Treatment.

Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.

H. Iwata, J. Sakamoto, S. Morita, 2004, Japanese journal of clinical oncology.

Clinical Trial Note Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer

H. Iwata, J. Sakamoto, S. Morita, 2004 .

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Y. Ohashi, K. Suemasu, S. Morita, 2012, Supportive Care in Cancer.

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): Validity and reliability in Japanese patients with advanced non-small-cell lung cancer

M. Shibuya, Y. Nishiwaki, M. Fukuoka, 2002, Quality of Life Research.

Laparoscopic Versus Open Surgery for Locally Advanced Rectal Cancer: Five-Year Survival Outcomes in a Large, Multicenter, Propensity Score-Matched Cohort Study

Atsuhiko Sumii, M. Okajima, S. Morita, 2021, Diseases of the colon and rectum.

A prospective randomized controlled trial of subcutaneous passive drainage for the prevention of superficial surgical site infections in open and laparoscopic colorectal surgery

S. Morita, M. Taguri, C. Kunisaki, 2014, International Journal of Colorectal Disease.

The Relationship Between Cephalogram Analysis and Oxygen Desaturation Index During Sleep in Patients Submitted for Mandibular Setback Surgery

Katsu Takahashi, S. Morita, T. Oga, 2018, The Journal of craniofacial surgery.

Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes: the Nagahama study.

Y. Kamatani, T. Kawaguchi, D. Gozal, 2020, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy

J. Sakamoto, M. Shiseki, S. Morita, 2017, International Journal of Clinical Oncology.

Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

J. Sakamoto, S. Morita, T. Kumagai, 2016, Oncology reports.

Reply: To PMID 25661580.

H. Date, S. Morita, A. Kawaguchi, 2015, The Annals of thoracic surgery.

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.

J. Sakamoto, S. Morita, T. Kumagai, 2018, Leukemia research.

International Primary Care Airway Guideline for Chronic Obstructive Pulmonary Disease and Screening Questionnaire for Japanese Subjects

N. Horita, G. Yasuda, S. Morita, 2016 .

Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment

S. Fukuhara, M. Mishima, S. Morita, 2008, Respirology.

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study

J. Sakamoto, S. Morita, Takeshi Takahashi, 2018, International Journal of Clinical Oncology.

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

J. Sakamoto, S. Morita, T. Kumagai, 2015, American journal of hematology.

Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn’s disease

S. Morita, Hiroto Kinoshita, Katsuaki Tanaka, 2014, BMC Research Notes.

Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas.

M. Sonobe, H. Date, S. Morita, 2021, Interactive cardiovascular and thoracic surgery.

Characteristics of high-echoic objects in the hepatic vessels of patients with cardiopulmonary arrest: a prospective cohort study

S. Morita, M. Sugiyama, S. Arata, 2011, Emergency Medicine Journal.

Risk factors for the severity and mortality of pneumococcal pneumonia: Importance of premorbid patients' performance status.

K. Kurashima, N. Takayanagi, R. Uozumi, 2016, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Effects of IL‐28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C

H. Fukuda, S. Morita, M. Taguri, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Original Articles: Adult Cardiac Adult Cardiac Surgery: Increased Graft Occlusion or String Sign in Composite Arterial Grafting for Mildly Stenosed Target Vessels

S. Takanashi, S. Morita, T. Shimokawa, 2022 .

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

J. Sakamoto, S. Morita, T. Kumagai, 2017, Cancer science.

A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.

M. Fukushima, E. Hatano, R. Doi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).

M. Ando, E. Baba, I. Hyodo, 2014 .

SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.

M. Buyse, J. Sakamoto, K. Tanabe, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, European journal of cancer.

M. Unno, K. Hasegawa, K. Muro, 2022, Langenbeck's Archives of Surgery.

Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas.

M. Kanda, S. Yamada, T. Fujii, 2010, Surgery.

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2015, Gastric Cancer.

Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2015, Gastric Cancer.

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

N. Taira, F. Hara, H. Iwata, 2022, Cancer science.

Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.

S. Morita, K. Sakamaki, Guosheng Yin, 2015, Journal of the National Cancer Institute.

Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreatology.

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

A. Gemma, M. Okada, S. Morita, 2018 .

Long-term outcome of mitral valve repair for infective endocarditis.

S. Takanashi, S. Morita, T. Shimokawa, 2009, The Annals of thoracic surgery.

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

A. Gemma, Y. Hosomi, S. Morita, 2018 .

TITE‐BOIN‐ET: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes

S. Morita, M. Taguri, Kentaro Takeda, 2019, Pharmaceutical statistics.

Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial

Mahbubur Rahman, J. Sakamoto, S. Morita, 2006, Trials.

Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer

I. Endo, Y. Goshima, T. Shimamura, 2011, Cancer science.

Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan

T. Hanyu, H. Hagiyama, S. Morita, 2016, Annals of the rheumatic diseases.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients

H. Iwata, Tsuyoshi Saito, N. Masuda, 2015, International Journal of Clinical Oncology.

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

J. Sakamoto, S. Morita, T. Kumagai, 2015, American journal of hematology.

SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer.

M. Buyse, J. Sakamoto, S. Morita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer

N. Kondo, S. Morita, Satoru Takahashi, 2021, Scientific Reports.

Final 3‐year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second‐line Treatment

J. Sakamoto, M. Hino, S. Kimura, 2018, Clinical lymphoma, myeloma & leukemia.

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

J. Sakamoto, S. Morita, T. Kumagai, 2020, Cancer science.

Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery.

N. Taira, F. Hara, S. Takashima, 2009, Japanese journal of clinical oncology.

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

J. Sakamoto, E. Morii, S. Morita, 2018, International journal of cancer.

Knowledge, attitude and practice regarding dengue among people in Pakse, Laos.

J. Sakamoto, S. Morita, Y. Yoshida, 2009, Nagoya journal of medical science.

Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease.

S. Umemura, S. Morita, K. Sakamoto, 2015, Journal of the American College of Cardiology.

Influence of Sex on€Mortality and Perioperative Outcomes in€Patients Undergoing TAVR

S. Umemura, S. Morita, K. Sakamoto, 2022 .

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.

A. Gemma, Y. Hosomi, S. Morita, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Posterior wall involvement attenuates predictive value of ST-segment elevation in lead V4R for right ventricular involvement in inferior acute myocardial infarction.

S. Umemura, S. Morita, K. Hibi, 2009, Journal of cardiology.

Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma

J. Sakamoto, H. Usuki, S. Morita, 2007, Journal of chemotherapy.

New clinical diagnostic criteria for eosinophilic chronic rhinosinusitis.

S. Morita, M. Tsukuda, T. Kaneko, 2011, Auris, nasus, larynx.

Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy

K. Kubota, S. Morita, M. Taguri, 2016, Supportive Care in Cancer.

Reliability and validity of the Functional Assessment of Chronic Illness Therapy–Spiritual (FACIT–Sp) for Japanese patients with cancer

T. Ohno, H. Tsujii, E. Matsushima, 2004, Supportive Care in Cancer.

A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.

Y. Kodera, J. Sakamoto, S. Morita, 2005, Japanese journal of clinical oncology.

Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan.

T. Aikou, S. Morita, M. Kitajima, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.

N. Taira, H. Iwata, N. Masuda, 2022, The Lancet. Oncology.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

N. Taira, F. Hara, H. Iwata, 2018, Japanese journal of clinical oncology.

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

E. Tokunaga, N. Kondo, N. Masuda, 2021, Breast Cancer Research and Treatment.

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

N. Masuda, S. Morita, S. Ohtani, 2021, International Journal of Clinical Oncology.

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study

Hideo Nakamura, T. Shibata, M. Nagane, 2022, Cancers.

Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2012 .

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

S. Morita, M. Toi, L. Chow, 2017, Endocrine-related cancer.

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

J. Sakamoto, S. Morita, T. Kono, 2013, Cancer Chemotherapy and Pharmacology.

Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures

M. Kanda, S. Yamada, T. Fujii, 2011, Annals of Surgical Oncology.

Hydroxyurea as an inhibitor of hepatitis C virus RNA replication

N. Kato, M. Ikeda, S. Morita, 2010, Archives of Virology.

A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer.

J. Sakamoto, H. Narahara, S. Morita, 2003, Japanese journal of clinical oncology.

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Kenichi Inoue, N. Masuda, S. Morita, 2020, Breast Cancer Research and Treatment.

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey.

N. Masuda, S. Morita, M. Toi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Sex onMortality and Perioperative Outcomes inPatients Undergoing TAVR

S. Umemura, S. Morita, K. Sakamoto, 2022 .

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

J. Sakamoto, S. Morita, N. Hosen, 2018, Cancer Immunology, Immunotherapy.

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

Y. Hosomi, M. Seike, S. Morita, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.

J. Sakamoto, S. Morita, 2007, Nagoya journal of medical science.

11 TRANSLATIONAL RESEARCH TO CLINICAL TRIAL ( RD ) for future Phase II studies to evaluate the effi cacy of the treatment

J. Sakamoto, S. Morita, 2007 .

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

M. Buyse, Tae Won Kim, J. Sakamoto, 2016 .

Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan

Y. Kodera, J. Sakamoto, S. Morita, 2006, Journal of chemotherapy.

G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

M. Kudo, N. Izumi, I. Sheen, 2015 .

Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial.

T. Fujii, Y. Kodera, H. Eguchi, 2016, Surgery.

Clinical pharmacology of daikenchuto assessed by transit analysis using radiopaque markers in patients with colon cancer undergoing open surgery: a multicenter double-blind randomized placebo-controlled study (JFMC39-0902 additional study)

K. Koda, S. Saji, S. Morita, 2016, Journal of Gastroenterology.

Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

S. Kitano, G. Wakabayashi, J. Sakamoto, 2015, Journal of the American College of Surgeons.

Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902)

J. Sakamoto, S. Morita, Masahiko Watanabe, 2015, Japanese journal of clinical oncology.

Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001)

M. Miyazaki, M. Kusano, H. Nagano, 2015, International Journal of Clinical Oncology.

AB0439 T Cell CD80/Cd86 Co-Stimulatory Blockade Does not Suppress CD8 (+) Subpopulation in the Course of 48-Week Treatment of Patients with Rheumatoid Arthritis

K. Ohmura, T. Mimori, S. Morita, 2014 .

Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.

J. Sakamoto, K. Kawakami, K. Omura, 2006, Oncology reports.

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

A. Gemma, M. Okada, S. Morita, 2019, The Lancet. Oncology.

A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2007, Japanese journal of clinical oncology.

Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.

Y. Ohashi, J. Sakamoto, S. Saji, 2004, Japanese journal of clinical oncology.

Psychosocial domain in quality of life as an independent prognostic factor for survival and tumor response in patients with advanced non-small cell lung cancer (NSCLS)

Satoshi Morita, Yasuo Ohashi, Kenji Eguchi, 2000 .

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer

M. Kataoka, Y. Yamada, M. Yoshimura, 2022, Scientific Reports.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies

Satoshi Morita, Moreno Ursino, Sarah Zohar, 2016, Statistical methods in medical research.

Bayesian Approach to Utilize Historical Control Data in Clinical Trials

Kentaro Takeda, Mari S. Oba, Tomoyuki Kakizume, 2015 .

Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets West

Satoshi Morita, S. Morita, 2011, Statistics in medicine.

Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis

Y. Yamaguchi, S. Morita, Z. Ikezawa, 2012, Archives of Dermatological Research.

Diagnostic criteria that can most accurately differentiate allergic bronchopulmonary mycosis from other eosinophilic lung diseases: A retrospective, single-center study.

Yotaro Takaku, N. Takayanagi, Y. Sugita, 2016, Respiratory investigation.

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

M. Nangaku, S. Morita, H. Hirakata, 2017, Renal Replacement Therapy.

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

K. Fushimi, Y. Imanaka, S. Morita, 2019, International Journal of Clinical Oncology.

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

S. Morita, M. Morimoto, Katsuaki Tanaka, 2010, Cancer.

Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

J. Sakamoto, H. Iishi, H. Narahara, 2011, Gastric Cancer.

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials

Y. Maehara, M. Kusano, J. Sakamoto, 2019, Surgery Today.

Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials

Y. Ohashi, J. Sakamoto, S. Morita, 2006, Cancer Immunology, Immunotherapy.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

T. Yoshimine, J. Sakamoto, S. Morita, 2016, International journal of cancer.

Knock Out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model

T. Kubo, T. Hla, S. Morita, 2014, PloS one.

Frequency of and variables associated with the EGFR mutation and its subtypes

A. Gemma, K. Uematsu, Tomoaki Tanaka, 2010, International journal of cancer.

Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital

T. Hanyu, H. Hagiyama, S. Morita, 2019, Arthritis Research & Therapy.

Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

Satoshi Morita, Tetsuhiro Kikuchi, Takuya Hayashi, 2017, Nature.

Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.

Y. Morino, Y. Ozaki, T. Murohara, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

K. Yamaguchi, T. Honjo, N. Matsumura, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease

Y. Kuroiwa, N. Matsumoto, S. Morita, 2012, Neurology.

Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.

M. Sonobe, H. Date, M. Hiraoka, 2014, European journal of cancer.

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2008, Journal of neurosurgery.

Association of IRF5 Polymorphisms with Susceptibility to Hemophagocytic Lymphohistiocytosis in Children

S. Morita, Hidenori Sato, T. Miyamae, 2011, Journal of Clinical Immunology.

Prognostic Impact of Lateral Pelvic Node Dissection on the Survival of Patients in Low Rectal Cancer Subgroups Based on Lymph Node Size

Atsuhiko Sumii, S. Morita, Seiichiro Yamamoto, 2021, Annals of Surgical Oncology.

Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial

Hirokazu Takahashi, S. Morita, A. Nakajima, 2012, BMC Cancer.

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

M. Fukuoka, K. Kiura, M. Satouchi, 2018, Cancer science.

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy.

S. Morita, Kazuhisa Takahashi, S. Yamanda, 2020, Lung cancer.

Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma?

H. Date, S. Morita, Cheng-long Huang, 2020, Surgery Today.

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

S. Morita, Kazuhisa Takahashi, Kunihiko Kobayashi, 2018, The oncologist.

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer

C. Ishioka, Masato Nakamura, S. Morita, 2021, Cancer science.

9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation

Toshio Shimizu, M. Fukuoka, S. Morita, 2014 .

Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

Y. Fujisawa, S. Morita, T. Kanekura, 2017, Oncoimmunology.

Androgen deprivation therapy prevents bladder cancer recurrence

Kotaro Suzuki, S. Morita, I. Ikeda, 2014, Oncotarget.

Reevaluation of the Effectiveness of Ramosetron for Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis

S. Morita, T. Mihara, K. Uchimoto, 2013, Anesthesia and analgesia.

Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2014, Annals of Surgical Oncology.

Matched Pair Analysis to Examine the Effects of a Planned Preoperative Exercise Program in Early Gastric Cancer Patients with Metabolic Syndrome to Reduce Operative Risk: The Adjuvant Exercise for General Elective Surgery (AEGES) Study Group

T. Yoshikawa, J. Sakamoto, Takanobu Yamada, 2014, Annals of Surgical Oncology.

A randomized phase II trial of preoperative exercise to reduce operative risk in gastric cancer patients with metabolic syndrome: adjuvant exercise for general elective surgery (AEGES) study group.

T. Yoshikawa, J. Sakamoto, S. Morita, 2008, Japanese journal of clinical oncology.

Lidocaine Concentration in Cerebrospinal Fluid after Epidural Administration: A Comparison between Epidural and Combined Spinal-Epidural Anesthesia

S. Morita, T. Kikuchi, Y. Kamiya, 2009, Anesthesiology.

Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial

M. Kanda, S. Yamada, T. Fujii, 2015, Annals of Surgical Oncology.

Application of the transorally inserted anvil (OrVil™) after laparoscopy-assisted total gastrectomy

I. Endo, S. Morita, C. Kunisaki, 2011, Surgical Endoscopy.

Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy

M. Kanda, S. Yamada, T. Fujii, 2015, Medicine.

Recurrence Pattern and Prognosis of Pancreatic Cancer After Pancreatic Fistula

M. Kanda, T. Fujii, H. Sugimoto, 2011, Annals of Surgical Oncology.

Clinicopathologic Study of Intrapancreatic Cancer Spread in Carcinoma of the Body and Tail of the Pancreas

S. Yamada, T. Fujii, H. Sugimoto, 2012, Pancreas.

Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas

M. Kanda, S. Yamada, T. Fujii, 2010, Annals of surgery.

Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design

Satoshi Morita, Junichi Sakamoto, J. Sakamoto, 2006, Pharmaceutical statistics.

Short-term results of a randomized study between laparoscopic and open surgery in elderly colorectal cancer patients

I. Endo, S. Morita, C. Kunisaki, 2014, Surgical Endoscopy.

Impact of Graft Quality and Fluid Overload on Postoperative Massive Ascites After Living Donor Liver Transplantation.

S. Yagi, S. Morita, S. Uemoto, 2019, Transplantation proceedings.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Satoshi Morita, Junji Uchida, Masahide Mori, 2015, Anticancer research.

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

S. Morita, K. Azuma, N. Yamamoto, 2021, JAMA oncology.

Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).

S. Morita, N. Yamamoto, K. Nakagawa, 2019, Clinical lung cancer.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study)

S. Morita, S. Negoro, N. Katakami, 2018, Cancer.

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).

M. Satouchi, T. Nishimura, S. Morita, 2015, Lung cancer.

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

M. Fukuoka, S. Morita, I. Okamoto, 2016, Japanese journal of clinical oncology.

A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.

S. Morita, T. Kijima, R. Takahashi, 2013, Lung cancer.

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

S. Morita, K. Kunimasa, T. Ishida, 2011, Lung cancer.

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

N. Masuda, N. Masuda, S. Morita, 2014, Cancer Chemotherapy and Pharmacology.

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

Y. Kono, M. Satouchi, R. Uozumi, 2020, BMC Cancer.

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma

H. Ueno, S. Morita, M. Ikeda, 2011, Pancreas.

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

J. Watanabe, S. Morita, S. Ohtani, 2022, BMC cancer.

International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)

Y. Kodera, Kazuhiro Yoshida, J. Ji, 2021, Annals of gastroenterological surgery.

Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

J. Watanabe, S. Morita, S. Ohtani, 2021, Scientific Reports.

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214

M. Yamaguchi, N. Masuda, S. Morita, 2021, Cancers.

Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.

H. Nishiyama, O. Ogawa, S. Morita, 2021, Urologic oncology.

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

N. Masuda, S. Morita, M. Toi, 2020, Investigational New Drugs.

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (

N. Masuda, Masato Takahashi, S. Morita, 2020, Trials.

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERA

N. Masuda, Masato Takahashi, S. Morita, 2020, Trials.

Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy

J. Watanabe, S. Morita, S. Ohtani, 2020, In Vivo.

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

N. Masuda, Masato Takahashi, S. Tanaka-Mizuno, 2020, Breast Cancer Research and Treatment.

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

S. Morita, Y. Koh, I. Okamoto, 2020, BMC Cancer.

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study

N. Masuda, Masato Takahashi, S. Morita, 2019, Japanese journal of clinical oncology.

Randomized phase II study of concurrent versus sequential alternating ge fi tinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations : NEJ 005 / TCOG 0902

A. Gemma, S. Morita, M. Kurihara, 2015 .

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

T. Yamanaka, S. Morita, M. Maemondo, 2019, International Journal of Clinical Oncology.

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

N. Ikeda, H. Saka, M. Satouchi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.

Y. Hosomi, S. Morita, K. Azuma, 2015, European journal of cancer.

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

S. Morita, Kunihiko Kobayashi, M. Maemondo, 2021, International Journal of Clinical Oncology.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Y. Ohe, M. Fukuoka, S. Morita, 2018, Lung cancer.

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations

A. Gemma, S. Morita, Kunihiko Kobayashi, 2018, ESMO Open.

Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.

A. Gemma, S. Morita, Kunihiko Kobayashi, 2015, Lung cancer.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

A. Gemma, S. Morita, M. Kurihara, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of UGT1A1 genotype upon toxicities of combination with low‐dose irinotecan plus platinum

Y. Ohashi, M. Shimada, S. Morita, 2016, Asia-Pacific journal of clinical oncology.

First-line Gemcitabine Versus Treatment of Physician’s Choice for Metastatic Breast Cancer: A Prospective Cohort Study

I. Endo, T. Ishikawa, S. Morita, 2021, AntiCancer Research.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Y. Takeda, H. Eguchi, Y. Doki, 2014, Journal of immunotherapy.

SNP (–617C>A) in ARE-Like Loci of the NRF2 Gene: A New Biomarker for Prognosis of Lung Adenocarcinoma in Japanese Non-Smoking Women

Y. Miyagi, Y. Hayashizaki, M. Lee, 2013, PloS one.

Virtual bronchoscopic navigation without X-ray fluoroscopy to diagnose peripheral pulmonary lesions: a randomized trial

S. Morita, T. Ishida, N. Shinagawa, 2016, BMC Pulmonary Medicine.

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

J. Sakamoto, S. Morita, T. Kumagai, 2016 .

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

J. Sakamoto, M. Hino, S. Kimura, 2013 .

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　- Fushimi AF Registry.

R. Uozumi, S. Morita, Y. Chun, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.

S. Morita, T. Hirano, S. Mishina, 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Carvedilol versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery: Rationale and Design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT)

S. Morita, Y. Kanmura, Y. Hayashi, 2006, Cardiovascular Drugs and Therapy.

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.

S. Morita, M. Taguri, I. Okamoto, 2013, Clinical lung cancer.

High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival

Takashi Ishikawa, Satoshi Morita, Yasushi Ichikawa, 2013, Breast Cancer Research and Treatment.

Single-incision laparoscopic surgery using colon-lifting technique for colorectal cancer: a matched case–control comparison with standard multiport laparoscopic surgery in terms of short-term results and access instrument cost

I. Endo, S. Morita, M. Taguri, 2012, Surgical Endoscopy.

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study

M. Satouchi, S. Kimura, S. Morita, 2016, Cancer science.

Prediction of the Pathogens That Are the Cause of Pneumonia by the Battlefield Hypothesis

Hitoshi Miyazawa, Satoshi Morita, Minoru Kanazawa, 2011, PloS one.

Relationship between Overall Survival and Response or Progression‐Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD‐1/PD‐L1 Antibodies

D. Carbone, P. Shields, G. Otterson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis

S. Morita, M. Taguri, M. Morimoto, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Prognostic Factors for Survival After Extended Pancreatectomy for Pancreatic Head Cancer: Influence of Resection Margin Status on Survival

S. Yamada, H. Sugimoto, Y. Kodera, 2009, Pancreas.

A Randomised Phase III Clinical trial of Combined Therapy with CPT-11/CDDP versus CPT-11 alone in Patients with advanced or Recurrent Gastric Cancer Resistant to S-1(Trics Study): Safety Analysis

J. Sakamoto, S. Morita, T. Tsujinaka, 2012 .

Bayesian population finding with biomarkers in a randomized clinical trial

Satoshi Morita, Peter Müller, P. Müller, 2017, Biometrics.

Practical Application of the Continual Reassessment Method to a Phase I Dose-Finding Trial in Advanced Breast Cancer

H. Iwata, J. Sakamoto, S. Morita, 2007 .

Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.

I. Endo, T. Ishikawa, K. Tsugawa, 2019, Breast.

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

M. Kohara, Y. Nakanishi, M. Mizokami, 2017, EBioMedicine.

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

N. Ikeda, M. Fukuoka, H. Saka, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Kazuhiro Yoshida, M. Buyse, J. Sakamoto, 2014, The Lancet. Oncology.

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

Satoshi Morita, Junichi Sakamoto, Masakazu Toi, 2008, Oncology.

Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2013, Annals of Surgical Oncology.

Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer

S. Morita, M. Toi, E. Suzuki, 2016, Breast Cancer.

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.

Kazuhiro Yoshida, H. Shimodaira, S. Morita, 2017, The lancet. Gastroenterology & hepatology.

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

J. Sakamoto, T. Enomoto, S. Morita, 2013, Journal of Cancer Research and Clinical Oncology.

The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.

I. Endo, T. Ishikawa, S. Morita, 2014, Journal of surgery and science.

Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.

Hideaki Takahashi, S. Morita, M. Taguri, 2012, The oncologist.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

K. Inoue, N. Masuda, S. Morita, 2018, Breast Cancer.

Open versus Laparoscopic Surgery for Advanced Low Rectal Cancer

T. Nishigori, S. Morita, Seiichiro Yamamoto, 2017, Annals of surgery.

Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.

S. Morita, T. Miyamae, M. Mori, 2011, British journal of clinical pharmacology.

Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.

Satoshi Morita, Etsuo Kunieda, Takeshi Kaneko, 2013, International journal of radiation oncology, biology, physics.

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study

T. Naoe, T. Miyamoto, S. Morita, 2018, Cancer science.

Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2020, Gastric Cancer.

Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.

H. Fukuda, S. Morita, M. Morimoto, 2014, Radiology.

Pattern of Lymph Node Metastasis Spread in Pancreatic Cancer

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreas.

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2021, Gastric Cancer.

Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 µg/Body) in a Patient with Chronic Myelomonocytic Leukemia

J. Sakamoto, I. Kawase, S. Morita, 2007 .

Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants

Kazuhiro Yoshida, T. Yoshikawa, J. Sakamoto, 2016, Supportive Care in Cancer.

Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments

Y. Kodera, J. Sakamoto, S. Morita, 2006, Gastric Cancer.

WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient

J. Sakamoto, I. Kawase, Toshio Tanaka, 2010, European journal of haematology.

Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial

Akira Takazawa, Satoshi Morita, S. Morita, 2020, Therapeutic Innovation & Regulatory Science.

Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.

Naoki Kagawa, Satoshi Morita, Naoya Hashimoto, 2012, Journal of neurosurgery.

Peripheral Endothelial Function and Cardiovascular Events in High‐Risk Patients

S. Umemura, S. Morita, M. Taguri, 2013, Journal of the American Heart Association.

Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure.

S. Fukuhara, M. Mishima, J. Yodoi, 2008, Antioxidants & redox signaling.

Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma

K. Ohta, S. Morita, K. Mitani, 2020, Annals of Hematology.

A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey

S. Morita, S. Adachi, M. Taguri, 2016, International Journal of Hematology.

Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer

J. Sakamoto, D. Ichikawa, E. Otsuji, 2010, Gastric Cancer.

A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer

Y. Maehara, S. Natsugoe, J. Sakamoto, 2008, Cancer Chemotherapy and Pharmacology.

The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis

T. Naoe, T. Kyo, K. Kawa, 2013, Bone Marrow Transplantation.

A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor

T. Naoe, T. Kyo, S. Kako, 2011, Leukemia.

Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302)

J. Kanda, Y. Kanda, S. Morita, 2018, International Journal of Hematology.

Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas

M. Kanda, T. Fujii, H. Sugimoto, 2011, Pancreas.

A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

Y. Tabata, S. Matsuda, H. Akiyama, 2016, International Orthopaedics.

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study

Toshio Shimizu, M. Fukuoka, S. Morita, 2020, Drugs in R&D.

Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis

K. Ohmura, T. Mimori, M. Hashimoto, 2020, Modern rheumatology.

A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

H. Tsuda, F. Akiyama, M. Kurosumi, 2018, Cancer medicine.

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry.

R. Uozumi, S. Morita, Y. Chun, 2015, Circulation journal : official journal of the Japanese Circulation Society.

A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial

Peter Müller, Satoshi Morita, Hiroyasu Abe, 2019, Biometrics.

Small, Moderate, and Large Changes, and the Minimum Clinically Important Difference in the University of California, San Diego Shortness of Breath Questionnaire

N. Horita, S. Morita, Y. Ishigatsubo, 2014, COPD.

A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)

M. Ando, Kaoru Tanaka, Y. Nakanishi, 2020, Cancer.

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)

E. Tokunaga, H. Iwata, Kenichi Inoue, 2021, Cancers.

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

C. Petropoulos, H. Iwata, N. Masuda, 2010, BMC Cancer.

Identification of Occult Parechymal Disease Such as Emphysema or Airway Disease Using Screening Computed Tomography

S. Fukuhara, S. Sone, K. Kubo, 2010, COPD.

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial

T. Mok, J. Yang, S. Morita, 2021, JTO clinical and research reports.

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003)

M. Satouchi, T. Nishimura, S. Morita, 2017, Cancer Chemotherapy and Pharmacology.

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study

N. Horita, S. Morita, Y. Ishigatsubo, 2013, Respiratory Research.

Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.

Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.

Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases

Meng Zhang, Satoshi Morita, Hiroshi Date, 2017, Clinical lung cancer.

Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis

S. Morita, S. Uemoto, T. Kaido, 2020, Annals of Surgical Oncology.

Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial

J. Soh, S. Toyooka, M. Aoe, 2019, International Journal of Clinical Oncology.

Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn’s disease

S. Morita, Hiroto Kinoshita, Katsuaki Tanaka, 2014, BMC Research Notes.

Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.

M. Nangaku, I. Narita, S. Morita, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Relative age effect on Nobel laureates in the UK

S. Morita, M. Taguri, Hisanori Fukunaga, 2013, JRSM short reports.

Higher level at admission and subsequent decline in hemoglobin in patients with acute pulmonary edema.

S. Umemura, S. Morita, K. Hibi, 2014, Circulation journal : official journal of the Japanese Circulation Society.

Risk assessment chart for curability of early gastric cancer with endoscopic submucosal dissection.

S. Morita, M. Taguri, M. Morimoto, 2011, Gastrointestinal endoscopy.

A New Statistical Model Identified Two-thirds of Clinical T1 Gastric Cancers as Possible Candidates for Endoscopic Treatment

S. Morita, T. Oshima, Y. Rino, 2015, Annals of Surgical Oncology.

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

C. Shimizu, M. Sugimoto, H. Sasano, 2014, Breast Cancer Research and Treatment.

Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2016, Gastric Cancer.

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2012, BMC Cancer.

Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis

J. Sakamoto, S. Morita, Takaho Tanaka, 2011, Gastric Cancer.

Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia

S. Morita, H. Miyamoto, Y. Kubota, 2013, BMC Urology.

Augmentation index is elevated in aortic aneurysm and dissection.

S. Morita, Y. Matsui, T. Tachibana, 2009, The Annals of thoracic surgery.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

T. Enomoto, S. Morita, N. Hosen, 2021, Journal of immunotherapy.

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

H. Sasano, N. Masuda, S. Morita, 2018, Cancer medicine.

Expanded living‐donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5‐5‐500 rule ‐ a retrospective study

S. Kawasaki, K. Hasegawa, H. Ohdan, 2019, Transplant international : official journal of the European Society for Organ Transplantation.

Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study.

Y. Toya, S. Umemura, N. Hirawa, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial)

M. Nangaku, I. Narita, S. Morita, 2016, Clinical and Experimental Nephrology.

Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities

S. Fukuhara, S. Morita, T. Akizawa, 2012, PloS one.

Quality of Life Improvements in Dialysis Patients Receiving Darbepoetin Alfa

S. Fukuhara, S. Morita, T. Akizawa, 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

M. Ando, Masato Nakamura, J. Sakamoto, 2020, Cancer medicine.

S. Fukuhara, S. Morita, T. Higashi, 2006, Quality of Life Research.

Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement.

S. Fukuhara, K. Chihara, S. Morita, 2007, European journal of endocrinology.

Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis

K. Ohmura, T. Mimori, M. Hashimoto, 2020, PloS one.

The impact of visceral obesity on surgical outcomes of laparoscopic surgery for colon cancer

I. Endo, S. Morita, Y. Ichikawa, 2014, International Journal of Colorectal Disease.

Laparoscopic Colorectal Cancer Surgery by a Colon Lifting-up Technique That Decreases the Number of Access Ports: Comparison by Propensity Scoring of Short-term and Long-term Outcomes With Standard Multiport Laparoscopic Surgery

I. Endo, S. Morita, M. Taguri, 2012, Surgical laparoscopy, endoscopy & percutaneous techniques.

Diagnostic accuracy of 18F-fluoride PET and PET/CT in patients with bone metastases: a systematic review and meta-analysis update

U. Tateishi, S. Morita, Tomio Inoue, 2013, Clinical and Translational Imaging.

A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor

U. Tateishi, S. Morita, M. Taguri, 2010, Annals of nuclear medicine.

INTERNAL LIMITING MEMBRANE CONTRAST AFTER STAINING WITH INDOCYANINE GREEN AND BRILLIANT BLUE G DURING MACULAR SURGERY

S. Morita, M. Taguri, T. Yamakawa, 2013, Retina.

Inner segment/outer segment junction assessed by spectral-domain optical coherence tomography in patients with idiopathic epiretinal membrane.

S. Morita, K. Kadonosono, M. Inoue, 2010, American journal of ophthalmology.

Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).

Takao Takahashi, Y. Ogata, S. Morita, 2015, Clinical colorectal cancer.

Effect of herbal medicine daikenchuto on oral and enteral caloric intake after liver transplantation: A multicenter, randomized controlled trial.

H. Eguchi, H. Ohdan, T. Yoshizumi, 2018, Nutrition.

Virtual bronchoscopic navigation combined with ultrathin bronchoscopy. A randomized clinical trial.

Satoshi Morita, Satoshi Oizumi, S. Morita, 2013, American journal of respiratory and critical care medicine.

Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer

Y. Himoto, S. Fujii, S. Morita, 2021, Abdominal Radiology.

Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.

M. Shibuya, K. Eguchi, Y. Ohashi, 2003, Japanese journal of clinical oncology.

Vaginal Douching in Cambodian Women: Its Prevalence and Association With Vaginal Candidiasis

H. Yatsuya, J. Sakamoto, S. Morita, 2009, Journal of epidemiology.

Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy

M. Mizumoto, T. Masui, Tadayuki Kou, 2016, International Journal of Clinical Oncology.

Changes in the sexual function of male patients with rectal cancer over a 2‐year period from diagnosis to 24‐month follow‐up: A prospective, multicenter, cohort study

S. Morita, N. Hoshino, K. Hida, 2020, Journal of surgical oncology.

Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases—a Japanese Nationwide Survey

G. Honda, I. Endo, M. Miyazaki, 2019, Journal of Gastrointestinal Surgery.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

A. Gemma, Y. Ichinose, Y. Ohe, 2019, International Journal of Clinical Oncology.

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.

T. Yamanaka, M. Ando, M. Fukuda, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bumetanide, an Inhibitor of Cation-chloride Cotransporter Isoform 1, Inhibits &ggr;-Aminobutyric Acidergic Excitatory Actions and Enhances Sedative Actions of Midazolam in Neonatal Rats

S. Morita, T. Mihara, Y. Kamiya, 2013, Anesthesiology.

Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.

T. Yamasaki, T. Habuchi, O. Ogawa, 2019, European urology oncology.

Relation between hyperinsulinemia and nonculprit plaque characteristics in nondiabetic patients with acute coronary syndromes.

F. Otsuka, S. Umemura, S. Morita, 2011, JACC. Cardiovascular imaging.

Individually different "weights" of quality of life assessment in patients with advanced nonsmall-cell lung cancer.

M. Shibuya, K. Eguchi, M. Fukuoka, 2003, Journal of clinical epidemiology.

Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial

Satoshi Morita, S. Morita, Shoichi Ohwada, 2016, Pharmaceutical statistics.

A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial).

T. Yoshikawa, K. Tanabe, S. Morita, 2012, Japanese journal of clinical oncology.

Prognostic Factors for a Composite End‐Point of Renal Outcomes in Patients With Chronic Kidney Disease

S. Fukuhara, S. Morita, T. Akizawa, 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).

T. Yoshikawa, M. Oka, J. Sakamoto, 2016, European journal of cancer.

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).

J. Sakamoto, Y. Hamamoto, S. Morita, 2014, The oncologist.

Proton Pump Inhibitor Use and the Ef ﬁ cacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT)

J. Sakamoto, S. Morita, Y. Park, 2021 .

Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.

Y. Hosomi, M. Ando, M. Kondo, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.

J. Sakamoto, I. Kawase, S. Morita, 2007, International journal of hematology.

Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

I. Endo, S. Morita, C. Kunisaki, 2011, Cancer Chemotherapy and Pharmacology.

Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)

M. Kusano, J. Sakamoto, I. Hyodo, 2022, BMC Cancer.

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

M. Kudo, N. Izumi, I. Sheen, 2018, The lancet. Gastroenterology & hepatology.

Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

M. Kudo, O. Matsui, S. Kaneko, 2019, Medical Oncology.

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

S. Morita, M. Taguri, M. Morimoto, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study

T. Yamasaki, R. Uozumi, S. Morita, 2022, International Journal of Translational Medicine.

Perspectives on the Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy

Chiun Hsu, S. Morita, A. Cheng, 2012, Liver Cancer.

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.

K. Uematsu, S. Morita, Kazuhisa Takahashi, 2019, The oncologist.

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)

S. Marubashi, A. Miyamoto, H. Nagano, 2015, Cancer Chemotherapy and Pharmacology.

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)

A. Miyamoto, H. Nagano, E. Hatano, 2014, Cancer Chemotherapy and Pharmacology.

Comprehensive data of 3,525 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: 2nd report of a nationwide survey in Japan.

G. Honda, I. Endo, M. Miyazaki, 2018, Journal of hepato-biliary-pancreatic sciences.

Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan

G. Honda, I. Endo, M. Miyazaki, 2018, Journal of hepato-biliary-pancreatic sciences.

NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.

A. Gemma, M. Okada, S. Morita, 2020 .

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

M. Ando, Masato Nakamura, J. Sakamoto, 2020, Cancer medicine.

High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

S. Morita, N. Nonomura, N. Masumori, 2014, BMC Cancer.

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

J. Sakamoto, S. Morita, Takeshi Takahashi, 2014 .

Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach

S. Morita, H. Inoue, M. Ichinose, 2017, International journal of chronic obstructive pulmonary disease.

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Y. Sunada, Y. Ohashi, S. Morita, 2009, Supportive Care in Cancer.

The impact of age on outcomes of elderly ED patients ventilated due to community acquired pneumonia.

S. Morita, T. Hifumi, Y. Koido, 2015, The American journal of emergency medicine.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

H. Sasano, N. Masuda, S. Morita, 2019, Cancer medicine.

Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

The Long-term Clinical Course of Chronic Eosinophilic Pneumonia.

Yotaro Takaku, N. Takayanagi, Y. Sugita, 2016, Internal medicine.

Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure

S. Morita, M. Iguchi, M. Abe, 2020, Heart.

Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives

Y. Kodera, Mahbubur Rahman, J. Sakamoto, 2004, Cancer Chemotherapy and Pharmacology.

Long‐term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi‐institutional Japanese study

G. Honda, I. Endo, M. Miyazaki, 2020, Journal of hepato-biliary-pancreatic sciences.

Statistical Contribution to Quality of Life (QOL) Evaluation

Y. Ohashi, S. Morita, 2001 .

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.

S. Morita, J. Uchida, H. Yoshioka, 2015, Lung cancer.

Phase II Study of S-1 in Combination with Trastuzumab for HER 2-positive Metastatic Breast Cancer

J. Sakamoto, Y. Miyoshi, T. Taguchi, 2014 .

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

I. Hyodo, H. Kuwano, K. Muro, 2014, Journal of Cancer Research and Clinical Oncology.

A Randomized Controlled Trial of Telemedicine for Long-Term Sleep Apnea CPAP Management.

T. Kuroda, T. Hirai, Y. Kondoh, 2020, Annals of the American Thoracic Society.

Injury and pre-hospital trauma care in Hanoi, Vietnam.

Satoshi Morita, Junichi Sakamoto, S. Morita, 2008, Injury.

WEEKLY ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER DURING CHEMOTHERAPY IN A RANDOMIZED PHASE III TRIAL

M. Shibuya, K. Eguchi, Y. Ohashi, 2004 .

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

K. Ishii, Y. Sunada, R. Takahashi, 2021, BMJ Open.

Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials.

Y. Kodera, J. Sakamoto, S. Morita, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk–benefit point of the Model for End‐stage Liver Disease score in patients waiting for deceased‐donor liver transplantation: A single‐center experience

S. Yagi, S. Morita, Y. Miyachi, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Long‐term quality of life of donors after living donor liver transplantation

S. Fukuhara, S. Morita, Y. Suzukamo, 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2019, Journal of Clinical Oncology.

Abstract P5-21-07: Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer

N. Masuda, S. Morita, M. Toi, 2018 .

Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

R. Hanajima, R. Takahashi, R. Uozumi, 2019, BMJ Open.

ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.

Toshio Shimizu, M. Fukuoka, S. Morita, 2015 .

Discrepancy Between Disability and the Severity of Low Back Pain: Demographic, Psychologic, and Employment-Related Factors

S. Fukuhara, S. Morita, Y. Suzukamo, 2006, Spine.

Association of HLA-A*02:06 and HLA-DRB1*04:05 with clinical subtypes of juvenile idiopathic arthritis

S. Morita, N. Mizuki, A. Kimura, 2011, Journal of Human Genetics.

A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial

M. Ando, Masato Nakamura, J. Sakamoto, 2018, Cancer medicine.

Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial

Hirokazu Takahashi, S. Morita, A. Nakajima, 2012, BMC Cancer.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.

T. Honjo, N. Matsumura, T. Baba, 2014 .

Basal and Ischemia-Induced Transcardiac Troponin Release into the Coronary Circulation in Patients with Suspected Coronary Artery Disease

S. Umemura, S. Morita, K. Sakamoto, 2013, PloS one.

Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies.

S. Morita, M. Morimoto, Katsuaki Tanaka, 2010, World journal of gastroenterology.

Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT.

M. Okada, S. Morita, M. Morimoto, 2009, Radiology.

Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial

A. Tsujikawa, S. Morita, N. Yoshimura, 2020, PloS one.

Title Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial

A. Tsujikawa, S. Morita, N. Yoshimura, 2020 .

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

F. Hara, N. Masuda, Ken-ichi Watanabe, 2018, Breast Cancer.

Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab.

T. Honjo, N. Matsumura, T. Baba, 2015 .

Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction.

Satoshi Morita, Masataka Taguri, Kazuo Kimura, 2013, Journal of the American College of Cardiology.

Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).

H. Imamura, N. Sugimoto, S. Morita, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Validation of the Patient Neurotoxicity Questionnaire (PNQ) During Taxane Chemotherapy in a Phase III Randomized Trial in Patients with Breast Cancer: N-SAS BC 02

Y. Sunada, Y. Ohashi, S. Morita, 2006 .

Transcutaneous oxygen pressure as a surrogate index of lower limb amputation.

S. Morita, M. Yokode, A. Kawaguchi, 2016, International angiology : a journal of the International Union of Angiology.

Effect of Daikenchuto (TJ-100) on postoperative bowel motility and on prevention of paralytic ileus after pancreaticoduodenectomy: a multicenter, randomized, placebo-controlled phase II trial (the JAPAN-PD study).

Y. Kodera, H. Nagano, J. Sakamoto, 2013, Japanese journal of clinical oncology.

Spiritual needs in cancer patients and spiritual care based on logotherapy

T. Ohno, H. Tsujii, E. Matsushima, 2005, Supportive Care in Cancer.

Proposal of a novel H category‐based classification of colorectal liver metastases based on a Japanese nationwide survey

G. Honda, I. Endo, M. Miyazaki, 2021, Journal of hepato-biliary-pancreatic sciences.

Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.

T. Yamanaka, M. Ando, M. Fukuda, 2016 .

Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer

Y. Miyagi, H. Grabsch, T. Yoshikawa, 2019, Journal of Cancer.

Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weighting

H. Fukuda, S. Morita, M. Morimoto, 2015, Journal of digestive diseases.

Title Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma : a propensity score-matching study

E. Hatano, S. Morita, S. Uemoto, 2019 .

International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).

Kazuhiro Yoshida, J. Ji, Y. Seto, 2018 .

Off-pump bilateral internal thoracic artery grafting in patients with left main disease.

S. Takanashi, S. Morita, T. Shimokawa, 2010, The Journal of thoracic and cardiovascular surgery.

Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study

J. Sakamoto, Takao Takahashi, S. Morita, 2013, International Journal of Clinical Oncology.

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)

M. Kanda, J. Sakamoto, M. Okajima, 2017, International Journal of Clinical Oncology.

Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

J. Sakamoto, T. Taguchi, S. Noguchi, 2011, Anticancer research.

Brief Report: Validation Study of the IASLC Histological Grading System of Invasive Lung Adenocarcinoma1.

A. Yoshizawa, M. Sonobe, H. Date, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus‐eluting stent in real‐world Japanese patients with coronary artery disease (OPERA): Study design and rationale

A. Hirayama, S. Morita, Masato Nakamura, 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Association of Education and Depressive Symptoms with Tooth Loss

T. Kawaguchi, F. Matsuda, T. Nakayama, 2020, Journal of dental research.

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

M. Satouchi, Kaoru Tanaka, S. Morita, 2013, Cancer.

Recombinant Human Fibroblast Growth Factor-2 Treatment to Prevent Femoral Head Collapse in Patients With Osteonecrosis of the Femoral Head: Trion, a Single-Arm, Historical Control, Multicenter, Phase II Trial

Sakae Tanaka, N. Sugano, S. Matsuda, 2021 .

Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model

Ying Yuan, Satoshi Morita, Jaeil Ahn, 2019, Statistical methods in medical research.

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

T. Nishimura, S. Morita, S. Nanjo, 2015, Cancer Chemotherapy and Pharmacology.

Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.

Y. Terauchi, S. Morita, T. Yamakawa, 2011, Endocrine journal.

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following fi

E. Oki, S. Morita, H. Nozawa, 2018, ESMO Open.

A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer

Y. Kakeji, J. Sakamoto, S. Morita, 2012, Gastric Cancer.

Local control of sphincter‐preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis

F. Fujita, M. Okajima, Takao Takahashi, 2017, Annals of Gastroenterological Surgery.

Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan.

S. Morita, A. Hagihara, D. Onozuka, 2021, Journal of Cancer Policy.

A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2018, Gastric Cancer.

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2016, International journal of cancer.

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)

S. Morita, W. Koizumi, Y. Sakata, 2014, Japanese journal of clinical oncology.

The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort

H. Grabsch, T. Yoshikawa, S. Morita, 2013, Cancer.

A Bayesian hierarchical mixture model for platelet‐derived growth factor receptor phosphorylation to improve estimation of progression‐free survival in prostate cancer

P. Thall, S. Morita, B. Bekele, 2010, Journal of the Royal Statistical Society. Series C, Applied statistics.

18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry

S. Morita, H. Hanaoka, T. Higuchi, 2010, Annals of nuclear medicine.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

M. Satouchi, S. Morita, F. Imamura, 2018, Lung cancer.

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

S. Morita, S. Oizumi, M. Maemondo, 2009 .

Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP

S. Morita, Nobuhiro Yamaguchi, Y. Ishigatsubo, 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer

N. Kondo, S. Morita, Satoru Takahashi, 2022, Scientific Reports.

Heterogeneity of the ef fi cacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients : prospective cohort study

S. Morita, Takashi Sato, Y. Ishigatsubo, 2022 .

Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction.

S. Umemura, S. Morita, M. Taguri, 2013, Journal of the American College of Cardiology.

A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer.

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2017 .

Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study.

S. Morita, M. Morimoto, Katsuaki Tanaka, 2013, European journal of radiology.

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer

S. Morita, I. Ikeda, M. Taguri, 2014, BMC Cancer.

Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial

Hirokazu Takahashi, S. Morita, A. Nakajima, 2012, BMC Cancer.

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

N. Ikeda, H. Saka, M. Satouchi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

S. Morita, S. Negoro, N. Katakami, 2018, Oncotarget.

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.

S. Morita, J. Uchida, H. Yoshioka, 2015, Lung cancer.

Relationship between Overall Survival and Response or Progression‐Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD‐1/PD‐L1 Antibodies

D. Carbone, P. Shields, G. Otterson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

S. Morita, N. Nonomura, N. Masumori, 2014, BMC Cancer.

Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial

S. Morita, Kentaro Takeda, 2018, Pharmaceutical statistics.

NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.

A. Gemma, Y. Hosomi, S. Morita, 2014 .

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma

H. Ueno, S. Morita, M. Ikeda, 2011, Pancreas.

Differences in negative T waves among acute coronary syndrome, acute pulmonary embolism, and Takotsubo cardiomyopathy

S. Umemura, S. Morita, K. Hibi, 2012, European heart journal. Acute cardiovascular care.

The impact of age on outcomes of elderly ED patients ventilated due to community acquired pneumonia.

S. Morita, T. Hifumi, Y. Koido, 2015, The American journal of emergency medicine.

A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

Y. Tabata, S. Matsuda, H. Akiyama, 2016, International Orthopaedics.

Physicians’ Choice in Using Internet and Fax for Patient Recruitment and Follow-up in a Randomized Controlled Trial

T. Fukui, J. Sakamoto, S. Morita, 2004, Methods of Information in Medicine.

T. Yoshikawa, Masato Nakamura, J. Sakamoto, 2019, Cancer Chemotherapy and Pharmacology.

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2008, Journal of neurosurgery.

Increased graft occlusion or string sign in composite arterial grafting for mildly stenosed target vessels.

S. Takanashi, S. Morita, T. Shimokawa, 2010, The Annals of thoracic surgery.

Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.

Y. Morino, Y. Ozaki, T. Murohara, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer

I. Endo, Y. Goshima, T. Shimamura, 2011, Cancer science.

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

H. Iwata, J. Sakamoto, S. Morita, 2008, Oncology.

Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.

Y. Terauchi, S. Morita, M. Taguri, 2016, Endocrine journal.

Clinical Outcomes of Subcutaneous and Visceral Adipose Tissue Characteristics Assessed in Patients Underwent Transcatheter Aortic Valve Replacement

Toshihiro Kobayashi, S. Morita, K. Takagi, 2020, CJC open.

Clinical and Radiographic Comparison of Influenza Virus-associated Pneumonia among Three Viral Subtypes.

Yotaro Takaku, T. Hoshi, T. Kanauchi, 2016, Internal medicine.

Y. Kodera, H. Nagano, J. Sakamoto, 2013, Japanese journal of clinical oncology.

Y. Kodera, T. Yoshikawa, J. Sakamoto, 2010, Japanese journal of clinical oncology.

Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreas.

Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.

Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase 3 trial (AXEPT).

J. Sakamoto, K. Muro, S. Morita, 2021, The oncologist.

BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes

Satoshi Morita, Kentaro Takeda, Masataka Taguri, 2018, Pharmaceutical statistics.

Rectal content and intrafractional prostate gland motion assessed by magnetic resonance imaging.

S. Morita, Tomio Inoue, S. Takebayashi, 2011, Journal of radiation research.

Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

Kazuhiro Yoshida, Masato Nakamura, H. Matsumoto, 2014 .

Effect of feedback in promoting adherence to an exercise programme: a randomized controlled trial.

S. Fukuhara, Y. Hayashino, S. Morita, 2011, Journal of evaluation in clinical practice.

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).

M. Satouchi, S. Morita, S. Fujita, 2013, Japanese journal of clinical oncology.

Combined prognostic utility of white blood cell count, plasma glucose, and glomerular filtration rate in patients undergoing primary stent placement for acute myocardial infarction.

C. Tei, M. Yamagishi, S. Morita, 2009, The American journal of cardiology.

ST-SEGMENT DEPRESSION IN LEAD AVR COMBINED WITH NO ST-SEGMENT ELEVATION IN LEAD V1 DIFFERENTIATES TAKOTSUBO CARDIOMYOPATHY FROM ANTERIOR ACUTE MYOCARDIAL INFARCTION

S. Umemura, S. Morita, K. Uchino, 2012 .

Recombinant human FGF-2 for the treatment of early-stage osteonecrosis of the femoral head: TRION, a single-arm, multicenter, Phase II trial.

Sakae Tanaka, N. Sugano, S. Matsuda, 2021, Regenerative medicine.

Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas

M. Kanda, S. Yamada, T. Fujii, 2011, Pancreas.

Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.

E. Shimosegawa, J. Hatazawa, T. Yoshimine, 2012, Journal of neurosurgery.

Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs

K. Yonemori, S. Morita, T. Urano, 2014, Therapeutic innovation & regulatory science.